Fulgent Genetics
Combines hereditary-cancer and pathology testing with a nanoencapsulated cancer-drug pipeline in clinical trials.
Something off on this page? Send us feedback.
Profile
Runs a next-generation-sequencing laboratory network spanning hereditary-cancer, reproductive-health, oncology, and rare-disease testing, anatomic pathology built through a string of cash-funded acquisitions, and contract sequencing for biopharma customers, while a wholly owned subsidiary advances a nanoencapsulated chemotherapy platform through mid-stage and early-stage cancer trials.
Operates a next-generation-sequencing laboratory spanning hereditary-cancer, reproductive-health, oncology, and rare-disease testing; an anatomic-pathology practice covering gastrointestinal, dermatopathology, breast, and hematopathology cases assembled through acquisitions; and a contract-sequencing unit serving biopharmaceutical and academic customers.
A wholly owned subsidiary runs a separate track: a proprietary nanoencapsulation drug-delivery platform advancing a lead paclitaxel candidate through a mid-stage trial in recurrent head-and-neck cancer, alongside a second candidate in early-stage dose escalation.
Testing volume during the pandemic built a large cash reserve funding every pathology acquisition without new debt or share issuance. The founder, who also chairs the board, holds roughly a third of outstanding shares, and operations concentrate in the United States alongside a minority stake in a Chinese joint venture.
The largest customer in the hereditary- and oncology-testing business has begun moving its testing in-house, a transition still working through segment results.
Company facts
Key statistics
Year to date −23.3% · Average volume (30d) 282.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Piper Sandler | Reiterate | Neutral | $15 | $19 | |
| May 5, 2026 | Piper Sandler | Reiterate | Neutral | $21 | $15 | |
| Nov 14, 2025 | Raymond James | Target | $25 | $36 | ||
| Aug 5, 2025 | UBS | Upgrade | Neutral | Buy | $30 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | −$0.46 | −$0.58 | −26.1% | $94.0M | $85.4M | −9.2% | −18.11% |
| May 1, 2026Q1 FY26 | −$0.35 | −$0.36 | −3.4% | $68.1M | $71.1M | +4.5% | +7.01% |
| Feb 27, 2026Q4 FY25 | $0.03 | $0.16 | +433.3% | $85.4M | $83.3M | −2.4% | −7.37% |
| Nov 7, 2025Q3 FY25 | −$0.24 | $0.14 | +158.3% | $85.4M | $84.1M | −1.5% | +3.03% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $73.5M | $81.8M | $84.1M | $83.3M | $71.1M | $85.4M | |
| Gross profit | $28.3M | $34.4M | $35.5M | $32.6M | $21.5M | $25.7M | |
| Operating income | −$19.8M | −$19.7M | −$15.4M | −$36.2M | −$34.6M | −$33.9M | |
| Net income | −$11.5M | −$19.0M | −$6.6M | −$23.4M | −$24.8M | −$29.5M | |
| Diluted EPS | −$0.37 | −$0.61 | −$0.21 | −$0.76 | −$0.80 | −$1.05 | |
| Gross margin | 38.6% | 42.1% | 42.2% | 39.1% | 30.2% | 30.1% | |
| Operating margin | -26.9% | -24.1% | -18.3% | -43.5% | -48.7% | -39.7% |
Fiscal years (4-quarter sums)FY21 $992.6M · FY22 $619.0M · FY23 $289.2M · FY24 $283.5M · FY25 $322.7M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $257.0M · Total debt $9.4M · Total assets $1.09B · Shareholders' equity $1.00B
Dividends
No dividends on record.
Ownership
Shares outstanding 28.40M · Float 17.03M · 60.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Barclays PLC | 2.34M | 7.57% | 13G | May 13, 2025 |
| BlackRock, Inc. | 2.29M | 8.05% | 13F | Aug 7, 2026 |
| Ramya Rao | 1.66M | 5.42% | 13G | Feb 7, 2025 |
| Acadian Asset Management LLC | 1.02M | 3.58% | 13F | Aug 13, 2026 |
| Hanlin Gao · officer: Chief Scientific Officer | 987.8K | 3.48% | Form 4 | Aug 28, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 27, 2026 | Hanlin Gao | officer: Chief Scientific Officer | −939 | $19.91 |
| Aug 27, 2026 | Jian Xie | officer: President and COO | −1,193 | $19.91 |
| May 27, 2026 | Hanlin Gao | officer: Chief Scientific Officer | −945 | $17.60 |
| May 27, 2026 | Jian Xie | officer: President and COO | −1,201 | $17.60 |
| Dec 2, 2025 | Hanlin Gao | officer: Chief Scientific Officer | −1,075 | $28.33 |
Peers
- NeoGenomics
Overlaps in oncology NGS, liquid biopsy, hereditary panels, and pathology
- Labcorp
Diversified clinical/genomic reference lab with anatomic pathology services
- Natera
Overlaps in reproductive health, hereditary cancer, and oncology liquid biopsy
- Guardant Health
Precision oncology liquid biopsy testing for cancer detection and screening
- Myriad Genetics
Molecular diagnostics for hereditary cancer risk and prenatal screening
- Castle Biosciences
Niche overlap in dermatopathology risk-stratification testing
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Fulgent Genetics | $19.61 | −0.05% | $556.9M | — | — | 1.7 | +4.4% |
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| Myriad Genetics | $3.16 | +0.48% | $298.5M | — | — | 0.4 | −10.5% |
| Castle Biosciences | $33.50 | +0.18% | $1.02B | — | — | 2.9 | +20.1% |
| Median | 27.7 | 41.3 | 2.4 | +15.7% |